本文選題：卵巢癌 + 靶向治療　； 參考：《重慶醫(yī)學(xué)》2016年30期

【摘要】：正女性生殖器官惡性腫瘤中,卵巢癌病死率位居首位[1],且發(fā)病率逐年增加。靶向治療指針對(duì)已明確的致癌位點(diǎn)(蛋白分子或基因片段)設(shè)計(jì)相應(yīng)治療藥物,藥物在體內(nèi)特異性結(jié)合致癌位點(diǎn)并發(fā)生作用,使癌細(xì)胞特異性死亡。這就要求靶向治療藥物同時(shí)具有殺傷作用和靶向作用,卵巢癌靶向治療中多種藥物對(duì)癌細(xì)胞的殺傷作用顯著,但因其靶向作用差導(dǎo)致的對(duì)正常
[Abstract]:Among the malignant tumors of female reproductive organs, the mortality of ovarian cancer is the highest [1], and the incidence of ovarian cancer is increasing year by year. Targeted therapy pointers are designed for specific carcinogenic sites (protein molecules or gene fragments), which specifically bind to carcinogenic sites in vivo and act on them, resulting in the specific death of cancer cells. This requires that targeted therapy drugs have both killing and targeting effects. In ovarian cancer targeted therapy, many drugs have significant killing effects on cancer cells, but due to their poor targeting effect, many drugs have a significant killing effect on cancer cells.
【作者單位】： 華北理工大學(xué)研究生學(xué)院;河北省唐山市工人醫(yī)院婦產(chǎn)科;
【分類號(hào)】：R737.31
，

本文編號(hào)：2079425